Core Viewpoint - The comparison between Progyny (PGNY) and HealthEquity (HQY) indicates that PGNY is currently more attractive to value investors due to its stronger earnings estimate revisions and better valuation metrics [1][3][7]. Valuation Metrics - PGNY has a forward P/E ratio of 13.82, while HQY has a forward P/E of 25.75, suggesting PGNY is undervalued compared to HQY [5]. - PGNY's PEG ratio is 0.83, indicating a more favorable valuation relative to its expected earnings growth, whereas HQY's PEG ratio is 1.19 [5]. - The P/B ratio for PGNY is 3.75, compared to HQY's P/B of 3.99, further supporting PGNY's superior valuation metrics [6]. Analyst Outlook - PGNY holds a Zacks Rank of 2 (Buy), reflecting a positive earnings estimate revision trend, while HQY has a Zacks Rank of 3 (Hold), indicating a less favorable outlook [3][7]. - The stronger estimate revision activity for PGNY suggests a more optimistic analyst outlook compared to HQY [7]. Value Grades - PGNY has been assigned a Value grade of B, while HQY has a Value grade of D, highlighting PGNY's better performance in key valuation metrics [6].
PGNY vs. HQY: Which Stock Is the Better Value Option?